Adverse Effects from Inappropriate Medication Administration via a Jejunostomy Feeding Tube

Nutrition in Clinical Practice

Volumn 18, Issue 5, 2003, Pages 402-405

  Dickerson, Roland N ^a   Tidwell, Angelina C ^a   Brown, Rex O ^a  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NICOTINIC ACID;

ADULT; ARTICLE; CASE REPORT; ENTERIC FEEDING; FEEDING APPARATUS; FLUSHING; HUMAN; HYPERLIPIDEMIA; IATROGENIC DISEASE; INTRAJEJUNAL DRUG ADMINISTRATION; JEJUNOSTOMY; JEJUNOSTOMY FEEDING TUBE; MALE; NAUSEA; PRACTICE GUIDELINE; PRURITUS; SIDE EFFECT; SWEAT GLAND DISEASE; TABLET; VOMITING;

EMESIS;

EID: 0345601151     PISSN: 08845336     EISSN: None     Source Type: Journal    
DOI: 10.1177/0115426503018005402     Document Type: Article

References (42)

1. Estoup M. Approaches and limitations of medication delivery in patients with enteral feeding tubes. Crit Care Nurse 14:68-72, 77-80, 1994
2. Gora ML, Tschampel MM, Visconti JA. Considerations of drug therapy in patients receiving enteral nutrition. Nutr Clin Pract 4:105-110, 1989
3. Smith CH, Bidlack WR. Dietary concerns associated with the use of medications. J Am Diet Assoc 84:901-914, 1984
4. Engle KK, Hannawa TE. Techniques for administering oral medications to critical care patients receiving continuous enteral nutrition. Am J Health Syst Pharm 56:1441-1444, 1999
5. Beckwith MC, Barton RG, Graves C. A guide to drug therapy in patients with enteral feeding tubes: Dosage form selection and administration methods. Hosp Pharm 32:57-64, 1997
6. Lutomski DM, Gora ML, Wright SM, et al. Sorbitol content of selected oral liquids. Ann Pharmacother 27:269-274, 1993
7. Hill DB, Henderson LM, McClain CJ. Osmotic diarrhea induced by sugar-free theophylline solution in critically ill patients. JPEN 15:332-336, 1991
8. Miller SJ, Oliver AD. Sorbitol content of selected sugar-free liquid medications. Hosp Pharm 28:741-744, 1993
9. Edes TE, Walk BE, Austin JL. Diarrhea in tube-fed patients: feeding formula not necessarily the cause. Am J Med 88:91-93, 1990
10. Dickerson RN, Melnik G. Osmolality of oral drug solutions and suspensions. Am J Hosp Pharm 45:832-834, 1988
11. Holtz L, Milton J, Sturek JK. Compatibility of medications with enteral feedings. JPEN 11:183-186, 1987
12. Niemiec PW Jr, Vanderveen TW, Morrison JI, et al. Gastrointestinal disorders caused by medication and electrolyte solution osmolality during enteral nutrition. JPEN 7:387-389, 1983
13. White KC, Harkavy KL. Hypertonic formula resulting from added oral medications. Am J Dis Child 136:931-933, 1982
14. Guenter PA, Settle RG, Perlmutter S, et al. Tube feeding-related diarrhea in acutely Ill patients. JPEN 15:277-280, 1991
15. Schiller LR. Drug-induced changes in bowel function. Contemp Gastro 2:29-35, 1989
16. Cutie AJ, Altman E, Lenkel L. Compatibility of enteral products with commonly employed drug additives. JPEN 7:186-191, 1983.
17. Burns PE, McCall L, Wirsching R. Physical compatibility of enteral formulas with various common medications. J Am Diet Assoc 88:1094-1096, 1988
18. Altman E, Cutie AJ. Compatibility of enteral products with commonly employed drug additives. Nutr Supp Serv 4:8-17, 1984
19. Fagerman KE, Ballou AE. Drug compatibilities with enteral feeding solutions coadministered by tube. Nutr Supp Serv 8:31-32, 1988
20. Bauer LA. Interference of oral phenytoin absorption by continuous nasogastric feedings. Neurology 32:570-572, 1982
21. Penrod LE, Allen JB, Cabacungan LR. Warfarin resistance and enteral feedings: 2 case reports and a supporting in vitro study. Arch Phys Med Rehabil 82:1270-1273, 2001
22. Healy DP, Brodbeck MC, Clendening CE. Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. Antimicrob Agents Chemother 40:6-10, 1996
23. Mueller BA, Brierton DG, Abel SR, et al. Effect of enteral feeding with ensure on oral bioavailabilities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother 38:2101-2105, 1994
24. Mimoz O, Binter V, Jacolot A, et al. Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enteral feeding to critically ill patients. Intensive Care Med 24:1047-1051, 1998
25. Faraji B, Yu PP. Serum phenytoin levels of patients on gastrostomy tube feeding. J Neurosci Nurs 30:55-59, 1998
26. Maynard GA, Jones KM, Guidry JR. Phenytoin absorption from tube feedings. Arch Intern Med 147:1821, 1987
27. Sneed RC, Morgan WT. Interference of oral phenytoin absorption by enteral tube feedings. Arch Phys Med Rehabil 69:682-684, 1988
28. Hooks MA, Longe RL, Taylor AT, et al. Recovery of phenytoin from an enteral nutrient formula. Am J Hosp Pharm 43:685-688, 1986
29. Cacek AT, DeVito JM, Koonce JR. In vitro evaluation of nasogastric administration methods for phenytoin. Am J Hosp Pharm 43:689-692, 1986
30. Petretich DA. Reversal of Osmolite-warfarin interaction by changing warfarin administration time. Clin Pharm 9:93, 1990
31. Kuhn TA, Garnett WR, Wells BK, et al. Recovery of warfarin from an enteral nutrient formula. Am J Hosp Pharm 46:1395-1399, 1989
32. Mitchell JE. Oral dosage forms that should not be crushed or chewed: 2002 update. Hosp Pharm 37:213-214, 2002
33. Chun AH, Shi HH, Achari R, et al. Lansoprazole: Administration of the contents of a capsule dosage formulation through a nasogastric tube. Clin Ther 18:833-842, 1996
34. Phillips JO, Olsen KM, Rebuck JA, et al. A randomized, pharmacokinetic and pharmacodynamic, cross-over study of duodenal or jejunal administration compared to nasogastric administration of omeprazole suspension in patients at risk for stress ulcers. Am J Gastroenterol 96:367-372, 2001
35. McAndrews KL Jr, Eastham JH. Omeprazole and lansoprazole suspensions for nasogastric administration. Am J Health Syst Pharm 56:81, 1999
36. Dunn A, White CM, Reddy P, et al. Delivery of omeprazole and lansoprazole granules through a nasogastric tube in vitro. Am J Health Syst Pharm 56:2327-2330, 1999
37. Quercia RA, Fan C, Liu X, et al. Stability of omeprazole in an extemporaneously prepared oral liquid. Am J Health Syst Pharm 54:1833-1836, 1997
38. Whelan AM, Price SO, Fowler SF, et al. The effect of aspirin on niacin-induced cutaneous reactions. J Fam Pract 34:165-168, 1992
39. Stern RH, Spence JD, Freeman DJ, et al. Tolerance to nicotinic acid flushing. Clin Pharmacol Ther 50:66-70, 1991
40. Goldberg A, Alagona P Jr, Capuzzi DM, et al. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. Am J Cardiol 85:1100-1105, 2000
41. Kashyap ML, McGovern ME, Berra K, et al. Long-term safety and efficacy of a once-daily niacin/loyastatin formulation for patients with dyslipidemia. Am J Cardiol 89:672-678, 2002
42. Keohane PP, Attrill H, Love M, et al. Relation between osmolality of diet and gastrointestinal side effects in enteral nutrition. BMJ 288:678-680, 1984